UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16a OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February, 2002
ALTAREX CORP.
(Exact name of Registrant as specified in its charter)
610 LINCOLN STREET
WALTHAM, MA, USA 02451
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
-------- -------
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
----- -----
On February 6, 2002, AltaRex Corp. (the "Company") announced new clinical
results from its ongoing analysis of its OvaRex(R) phase IIb trial in metastatic
ovarian cancer. The full text of the press release issued in connection with the
announcement is filed as Exhibit 99.1 to this Current Report on Form 6-K and is
incorporated herein by reference.
INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION
- ----------- -----------
99.1 Press Release Regarding OvaRex(R) Phase IIb Clinical Results,
dated February 6, 2002.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Company has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ALTAREX CORP.
By: /s/ Edward M. Fitzgerald
-------------------------------------
Name: Edward M. Fitzgerald
Title: Senior Vice President and
Chief Financial Officer
Date: February 7, 2002